{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-016562","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.534940+00:00","generated_at":"2026-05-23T03:09:28.678936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%","bullets":["Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).","GAAP operating loss $146M (non-GAAP $117M); FY2025 revenue guidance raised to $725-750M from >$600M.","Donidalorsen PDUFA Aug 21, 2025; olezarsen Phase 3 sHTG data Q3 2025; ION582 Phase 3 Angelman Q2 2025.","Sapablursen licensed to Ono for $280M upfront; potential $660M milestones plus mid-teen royalties.","Cash & investments $2.1B at Mar 31; expected ~$1.9B year-end after $280M Q2 inflow."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-016562","json":"https://secwatch.observer/filing/0001140361-25-016562.json","markdown":"https://secwatch.observer/filing/0001140361-25-016562.md","text":"https://secwatch.observer/filing/0001140361-25-016562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/0001140361-25-016562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/ef20048172_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:09:28.678936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}